Is new better than tried and tested? Topical atopic dermatitis treatment in context
- PMID: 29595233
- PMCID: PMC6214668
- DOI: 10.1111/bjd.16316
Is new better than tried and tested? Topical atopic dermatitis treatment in context
Conflict of interest statement
C.F. has acted as consultant to Sanofi/Regeneron and Genentech/Roche.
Comment on
-
Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild-moderate atopic dermatitis.Br J Dermatol. 2018 Mar;178(3):663-664. doi: 10.1111/bjd.16047. Epub 2017 Nov 30. Br J Dermatol. 2018. PMID: 29194568 No abstract available.
-
Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.Br J Dermatol. 2018 Mar;178(3):659-662. doi: 10.1111/bjd.16046. Epub 2017 Dec 3. Br J Dermatol. 2018. PMID: 29205284
References
-
- Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109–22. - PubMed
-
- Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140:633–43. - PubMed
-
- Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102(4 Pt 1):637–44. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
